ConductScience.org, home

Paper20125090

Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].

Di Cosimo S and 1 other. Nat Rev Clin Oncol, 2010. Cited by 136 papers, by iCite.

Cite this record

ConductScience Library. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Papers, record 20125090. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20125090

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].
PubMed
Journal
Nat Rev Clin Oncol
PubMed
Year
2010
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
136
iCite
Relative citation ratio, by iCite
2.88
iCite
Revised in PubMed
2026-10-13
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Di Cosimo SSerena
2Baselga JJosé

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Biomarkers, TumorMajor topic
Breast NeoplasmsMajor topic
Enzyme InhibitorsMajor topic
Female
Humans
Neoplasm Staging
Treatment Outcome

Source PubMed

Download CSV of topics

References61

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119075286Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.J Clin Oncol2009https://conductscience.org/library/papers/19075286PubMed
212204533Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.Cancer Cell2002https://conductscience.org/library/papers/12204533PubMed
312223530The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.Pharmacol Rev2002https://conductscience.org/library/papers/12223530PubMed
416985247Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.J Natl Cancer Inst2006https://conductscience.org/library/papers/16985247PubMed
518829560NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.Cancer Res2008https://conductscience.org/library/papers/18829560PubMed
619617568Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.Proc Natl Acad Sci U S A2009https://conductscience.org/library/papers/19617568PubMed
715681523Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.J Clin Oncol2005https://conductscience.org/library/papers/15681523PubMed
812359757Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.Cancer Res2002https://conductscience.org/library/papers/12359757PubMed
916000569A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.Clin Cancer Res2005https://conductscience.org/library/papers/16000569PubMed
1020124182Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.J Clin Oncol2010https://conductscience.org/library/papers/20124182PubMed
1115489913The interplay between Src family kinases and receptor tyrosine kinases.Oncogene2004https://conductscience.org/library/papers/15489913PubMed
1219249681Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.Cancer Cell2009https://conductscience.org/library/papers/19249681PubMed
1311208825Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.J Clin Oncol2001https://conductscience.org/library/papers/11208825PubMed
1417064066
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
J Med Chem2006https://conductscience.org/library/papers/17064066PubMed
153798106Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science1987https://conductscience.org/library/papers/3798106PubMed
1619289619Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.J Clin Oncol2009https://conductscience.org/library/papers/19289619PubMed
179442882Cellular functions regulated by Src family kinases.Annu Rev Cell Dev Biol1997https://conductscience.org/library/papers/9442882PubMed
1817397528FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.Breast Cancer Res2007https://conductscience.org/library/papers/17397528PubMed
1917440164Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.J Natl Cancer Inst2007https://conductscience.org/library/papers/17440164PubMed
2017438091The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res2007https://conductscience.org/library/papers/17438091PubMed

See all 61 referencesDownload CSV of references

Cited by88

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 136 citations.

PMIDTitleJournalYearIn PapersSource
42438567Unveiling isoleucyl-tRNA synthetase 2 as a novel driver of breast cancer via β-catenin pathway activation.J Cell Commun Signal2026https://conductscience.org/library/papers/42438567PubMed
42258564Integrated Analysis Identifies an Anoikis-Related Gene Signature for Predicting Prognosis in Patients With Triple-Negative Breast Cancer.IET Syst Biol2026https://conductscience.org/library/papers/42258564PubMed
40574091Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics2025https://conductscience.org/library/papers/40574091PubMed
40555914KLF13 promotes breast cancer progression through the HTRA1 and the Hedgehog signaling pathway.Breast Cancer2025https://conductscience.org/library/papers/40555914PubMed
39775383Targeting necroptosis in MCF-7 breast cancer cells: In Silico insights into 8,12-dimethoxysanguinarine from Eomecon Chionantha through molecular docking, dynamics, DFT, and MEP studies.PLoS One2025https://conductscience.org/library/papers/39775383PubMed
39335478CAF-Associated Genes in Breast Cancer for Novel Therapeutic Strategies.Biomedicines2024https://conductscience.org/library/papers/39335478PubMed
38005235Recent Advances in Drug Discovery for Triple-Negative Breast Cancer Treatment.Molecules2023https://conductscience.org/library/papers/38005235PubMed
37025579Altered Expression of CYSLTR1 is Associated With Adverse Clinical Outcome in Triple Negative Breast Tumors: An In Silico Approach.Eur J Breast Health2023https://conductscience.org/library/papers/37025579PubMed
36133695A conjugated 2D covalent organic framework as a drug delivery vehicle towards triple negative breast cancer malignancy.Nanoscale Adv2022https://conductscience.org/library/papers/36133695PubMed
34907082Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.Clin Cancer Res2022https://conductscience.org/library/papers/34907082PubMed
34069461Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.Nutrients2021https://conductscience.org/library/papers/34069461PubMed
33584787Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer.Front Genet2020https://conductscience.org/library/papers/33584787PubMed
32821156The Clinical Relevance and Function of Krüppel-Like Factor 16 in Breast Cancer.Cancer Manag Res2020https://conductscience.org/library/papers/32821156PubMed
32784973Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives.Int J Mol Sci2020https://conductscience.org/library/papers/32784973PubMed
32675392LncRNA NEAT1 accelerates breast cancer progression through regulating miR-410-3p/ CCND1 axis.Cancer Biomark2020https://conductscience.org/library/papers/32675392PubMed
32186756Effects of cisplatin on the proliferation, invasion and apoptosis of breast cancer cells following β‑catenin silencing.Int J Mol Med2020https://conductscience.org/library/papers/32186756PubMed
32062536
Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Breast2020https://conductscience.org/library/papers/32062536PubMed
32054043Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.Int J Mol Sci2020https://conductscience.org/library/papers/32054043PubMed
31938048PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness.Theranostics2020https://conductscience.org/library/papers/31938048PubMed
31801619ZMYND10, an epigenetically regulated tumor suppressor, exerts tumor-suppressive functions via miR145-5p/NEDD9 axis in breast cancer.Clin Epigenetics2019https://conductscience.org/library/papers/31801619PubMed

See all 88 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ERBB32065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene
HSP90AA13320PubTator's text mininghttps://conductscience.org/library/genes/3320NCBI Gene
MET4233PubTator's text mininghttps://conductscience.org/library/genes/4233NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20125090

GET https://conductscience.org/api/papers/v1/20125090/references?page=2